491 results on '"Bellon, Jennifer R."'
Search Results
2. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
3. Intraoperative Pathology Assessment May Lead to Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer Patients Undergoing Upfront Mastectomy
4. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
5. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline
6. Impact of Prepectoral vs. Subpectoral Tissue Expander Placement on Post-mastectomy Radiation Therapy Delivery: A Retrospective Cohort Study
7. ASO Visual Abstract: Intraoperative Pathology Assessment May Lead to Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer Patients Undergoing Upfront Mastectomy
8. Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
9. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
10. MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer
11. Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial.
12. Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
13. Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes
14. Time-Driven Activity-Based Costing in Breast Cancer Care Delivery
15. Clinicogenomic characterization of inflammatory breast cancer
16. A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer
17. Utilization and predictors of postmastectomy radiation receipt in an Oncology Center in Zimbabwe
18. ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations
19. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists
20. A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
21. Quality of Life and Limb: Reducing Lymphedema Risk After Breast Cancer Therapy
22. Long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ
23. Effects of Postmastectomy Radiation Therapy on Immediate Tissue Expander and Acellular Dermal Matrix Reconstruction: Results of a Prospective Clinical Trial
24. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade
25. ASO Visual Abstract: Time-Driven Activity-Based Costing (TDABC) in Breast Cancer Care Delivery
26. Preoperative Risk Factors for Lymphedema in Inflammatory Breast Cancer.
27. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline
28. Preoperative Risk Factors for Lymphedema in Inflammatory Breast Cancer
29. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline
30. Correction to: Time-Driven Activity-Based Costing in Breast Cancer Care Delivery
31. ASO Visual Abstract: Optimizing Axillary Management in Clinical T1–2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes
32. Looking Back: International Practice Patterns in Breast Radiation Oncology From a Case-Based Survey Across 54 Countries During the First Surge of the COVID-19 Pandemic
33. SP33. Optimizing Patient Selection for Lympha in Patients with Inflammatory Breast Cancer
34. D84. Pre-operative Lymphedema Risk Factors in Patients with Inflammatory Breast Cancer: Optimizing Patient Selection for LYMPHA
35. Dosimetric Inhomogeneity Predicts for Long-Term Breast Pain After Breast-Conserving Therapy
36. Overcoming Resistance — Omission of Radiotherapy for Low-Risk Breast Cancer
37. Prospective assessment of deep inspiration breath-hold using 3-dimensional surface tracking for irradiation of left-sided breast cancer
38. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer
39. The Impact of Reexcision and Residual Disease on Local Recurrence Following Breast-Conserving Therapy
40. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy
41. Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer
42. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications
43. Beyond Mean Heart Dose: Cardiac Metrics for the Modern Era
44. Management of the Regional Lymph Nodes Following Breast-Conservation Therapy for Early-Stage Breast Cancer: An Evolving Paradigm
45. Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.
46. Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer
47. Regional Nodal Management After Preoperative Systemic Therapy
48. In Reply to Yilmaz et al.
49. Impact of Margin Status on Local Recurrence After Mastectomy for Ductal Carcinoma In Situ
50. Automation of clip localization in Digital Tomosynthesis for setup of breast cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.